相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Structural modification aimed for improving solubility of lead compounds in early phase drug discovery
Bhanuranjan Das et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2022)
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy
Mohsan Iftikhar et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Aini Vuorinen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid
Isabel V. L. Wilkinson et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid
Maria Chatzopoulou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model
Arran Babbs et al.
TETRAHEDRON (2020)
2-Arylbenzo[d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy
Arran Babbs et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet
Francesco Muntoni et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
Akinori Nakamura
JOURNAL OF PERSONALIZED MEDICINE (2019)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management (vol 17, pg 251, 2018)
J. F. Zimmermann et al.
LANCET NEUROLOGY (2018)
The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
Simon Guiraud et al.
EXPERT OPINION ON ORPHAN DRUGS (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
David J. Birnkrant et al.
LANCET NEUROLOGY (2018)
Pharmacological advances for treatment in Duchenne muscular dystrophy
Simon Guiraud et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single-and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
Valeria Ricotti et al.
PLOS ONE (2016)
Second-generation compound for the modulation of utrophin in the therapy of DMD
Simon Guiraud et al.
HUMAN MOLECULAR GENETICS (2015)
Data Warrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis
Thomas Sander et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, Following Single-and Multiple-Dose Administration to Healthy Male Adult Volunteers
Jon Tinsley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy
Rosario Santos et al.
JOURNAL OF HUMAN GENETICS (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy
Daniel R. Chancellor et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Frank Lovering et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Efficient synthesis of a complete donor/acceptor bis(aryl)diyne family
BT Holmes et al.
SYNTHETIC COMMUNICATIONS (2003)
分享论文
